<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1693">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05139121</url>
  </required_header>
  <id_info>
    <org_study_id>MR-100A-01-TD-3001</org_study_id>
    <nct_id>NCT05139121</nct_id>
  </id_info>
  <brief_title>Study of the Safety and Efficacy of MR-100A-01 in Approximately 1200 Healthy Women for up to 13 Cycles</brief_title>
  <official_title>A Phase 3, Multicenter, Open-Label, Single Arm Study of MR-100A-01 in Women of Childbearing Potential to Evaluate Contraceptive Efficacy and Safety</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mylan Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mylan Technologies Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Mylan Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study of the contraceptive efficacy, cycle control, safety, and tolerability of MR-100A-01 in&#xD;
      approxmiately 1200 women for up to 13 cycles&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      MR-100A-01 is a TDS of norelgestromin 4.86 mg/ethinyl estradiol 0.264 mg. This study will&#xD;
      evaluate the contraceptive efficacy, cycle control, safety, and tolerability of MR-100A-01.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 26, 2021</start_date>
  <completion_date type="Anticipated">May 2023</completion_date>
  <primary_completion_date type="Anticipated">May 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Contraceptive efficacy of MR-100A-01 when used over thirteen 28-day cycles in healthy, post-menarcheal, premenopausal, heterosexually active female subjects of childbearing potential who are at least 16 years of age and at risk of pregnancy</measure>
    <time_frame>12 months (13 cycles)</time_frame>
    <description>The primary efficacy endpoint will be pregnancy rate described by Pearl Index (PI). PI is defined as the number of pregnancies per 100 women-years times 100</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cycle-wise pregnancy rates over 1 year evaluated using life table analysis [secondary efficacy]</measure>
    <time_frame>12 months (13 cycles)</time_frame>
    <description>The rate of cycle-wise pregnancies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative pregnancy rates over 1 year evaluated using life table analysis [secondary efficacy]</measure>
    <time_frame>12 months (13 cycles)</time_frame>
    <description>The rate of cycle-wise pregnancies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Method failure Pearl Index (PI) [secondary efficacy]</measure>
    <time_frame>12 months (13 cycles)</time_frame>
    <description>The method failure PI is defined as PI among all complete or incomplete on therapy cycles in which intercourse occurred and protocol guidelines were not followed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events (AEs) [safety and tolerability]</measure>
    <time_frame>12 months (13 cycles)</time_frame>
    <description>The number of AEs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of serious adverse events (SAEs) [safety and tolerability]</measure>
    <time_frame>12 months (13 cycles)</time_frame>
    <description>The number of SAEs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of application site reactions [safety and tolerability]</measure>
    <time_frame>12 months (13 cycles)</time_frame>
    <description>The number of application site reactions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of episodes of scheduled and unscheduled bleeding [cycle control]</measure>
    <time_frame>12 months (13 cycles)</time_frame>
    <description>The number of incidences of scheduled and unscheduled bleeding</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days of scheduled and unscheduled bleeding [cycle control]</measure>
    <time_frame>12 months (13 cycles)</time_frame>
    <description>The observed number of days of scheduled or unscheduled bleeding</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects reporting scheduled and unscheduled bleeding [cycle control]</measure>
    <time_frame>12 months (13 cycles)</time_frame>
    <description>The number of subjects reporting scheduled and unscheduled bleeding</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adhesion performance as measured by adhesion scores [patch adhesion]</measure>
    <time_frame>12 months (13 cycles)</time_frame>
    <description>The descriptive figures of adhesion performance</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">1200</enrollment>
  <condition>Contraception</condition>
  <arm_group>
    <arm_group_label>MR-100A-01</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MR-100A-01 is a transdermal delivery system designed to deliver daily hormone exposure of Norelgestromin and Ethinyl Estradiol</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MR-100A-01</intervention_name>
    <description>Transdermal contraceptive delivery system</description>
    <arm_group_label>MR-100A-01</arm_group_label>
    <other_name>Transdermal contraceptive delivery system</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy, post-menarcheal and premenopausal women at risk of pregnancy who are at least&#xD;
             16 years of age with no upper age limit. Post-menarcheal female subjects who are at&#xD;
             risk of pregnancy, and &lt;18 years are eligible provided that:&#xD;
&#xD;
               1. Applicable national, state, and local laws allow the subject to consent to sexual&#xD;
                  intercourse,&#xD;
&#xD;
               2. Applicable national, state, and local laws allow subjects in this age group to&#xD;
                  consent/assent to receive contraceptive services, and&#xD;
&#xD;
               3. All applicable laws and regulations regarding the informed consent/assent of the&#xD;
                  subjects to participate in clinical trials are observed.&#xD;
&#xD;
          2. Desires to avoid pregnancy, is seeking to use hormonal contraception for at least 1&#xD;
             year.&#xD;
&#xD;
          3. Has negative UPT results at screening and at enrollment visits.&#xD;
&#xD;
          4. Has normal, regular menstrual cycles that are between 21 and 35 days.&#xD;
&#xD;
          5. Engages in regular heterosexual vaginal intercourse.&#xD;
&#xD;
          6. Agrees not to use other contraceptives or other methodology to prevent pregnancy&#xD;
             during the study.&#xD;
&#xD;
          7. Able to understand and voluntarily provide written informed consent or assent to&#xD;
             participate in the study.&#xD;
&#xD;
          8. Able to understand and willing to be compliant with study procedures.&#xD;
&#xD;
          9. Willing to accept a risk of pregnancy.&#xD;
&#xD;
         10. Has demonstrated ability to complete e-Diary.&#xD;
&#xD;
         11. Planning to reside within a reasonable driving/ public transport distance of the&#xD;
             research site (approximately 150 miles) for around 12 months (13 cycles).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known or suspected pregnancy or planning pregnancy during next 12 months.&#xD;
&#xD;
          2. Subjects with known hypersensitivity or intolerance to estrogens, progestins, or any&#xD;
             components of the MR-100A-01 product.&#xD;
&#xD;
          3. History or presence of dermal sensitivity to topical applications including bandages,&#xD;
             surgical tape.&#xD;
&#xD;
          4. Known infertility (current or known history) or history of sterilization in either&#xD;
             partner.&#xD;
&#xD;
          5. Received injectable hormonal contraceptive therapy within 10 months of study&#xD;
             enrollment.&#xD;
&#xD;
          6. Use of hormonal contraceptive implants (still implanted or only less than 3&#xD;
             consecutive spontaneous menses have occurred since removal at enrollment).&#xD;
&#xD;
          7. Has hormonal/non-hormonal intrauterine device (IUD) in place without one spontaneous&#xD;
             menses after removal or had progestin releasing IUD in place within 3 months of study&#xD;
             enrollment.&#xD;
&#xD;
          8. Recent surgical or medical abortion, miscarriage, ectopic pregnancy, or vaginal or&#xD;
             cesarean delivery and have had less than 3 consecutive, spontaneous menses or&#xD;
             withdrawal bleeding episodes prior to enrollment.&#xD;
&#xD;
          9. Subjects lactating at the time of screening into the study.&#xD;
&#xD;
         10. Anticipates routine use of condoms or any other form of back-up contraception for&#xD;
             protection from sexually transmitted infections during the study or for emergency&#xD;
             contraception.&#xD;
&#xD;
         11. Subjects having a known contraindication to combined hormonal contraception as listed&#xD;
             below:&#xD;
&#xD;
               1. Smoker who is ≥35 years old.&#xD;
&#xD;
               2. History or presence of ischemic heart disease, coronary artery disease,&#xD;
                  myocardial infarction, stroke, other cerebrovascular diseases including transient&#xD;
                  ischemic attacks (TIAs), valvular heart disease with complications (pulmonary&#xD;
                  hypertension, risk for atrial fibrillation, or history of subacute bacterial&#xD;
                  endocarditis), peripartum cardiomyopathy.&#xD;
&#xD;
               3. History or presence of hypertension (including adequately controlled&#xD;
                  hypertension) or hypertension with vascular disease or elevated blood pressure&#xD;
                  (BP) defined as systolic BP ≥140 mm Hg or diastolic BP ≥90 mm Hg, measured in&#xD;
                  sitting position after 5 minutes of rest.&#xD;
&#xD;
               4. History or presence of deep vein thrombosis/pulmonary embolism or superficial&#xD;
                  venous thrombosis.&#xD;
&#xD;
               5. Has any comorbid condition that may require major surgery with prolonged&#xD;
                  immobilization during the study period.&#xD;
&#xD;
               6. Subjects with known inherited or acquired hypercoagulopathy.&#xD;
&#xD;
               7. History or presence of systemic lupus erythematosus.&#xD;
&#xD;
               8. History or presence of neurological conditions including migraine or multiple&#xD;
                  sclerosis with prolonged immobility.&#xD;
&#xD;
               9. History or presence of or suspected carcinoma of breast.&#xD;
&#xD;
              10. Has diabetes mellitus with vascular disease.&#xD;
&#xD;
              11. Has inflammatory bowel disease.&#xD;
&#xD;
              12. Medically treated or presence of symptomatic gall bladder disease.&#xD;
&#xD;
              13. History of combined hormonal contraceptive/pregnancy related&#xD;
                  cholestasis/jaundice.&#xD;
&#xD;
              14. Presence of liver disease.&#xD;
&#xD;
              15. History of organ transplantation within 5 years before screening.&#xD;
&#xD;
              16. Subject has requirement to be on treatment with medications prohibited during&#xD;
                  study.&#xD;
&#xD;
         12. Known or suspected estrogen or progestin sensitive malignant or premalignant&#xD;
             conditions.&#xD;
&#xD;
         13. History of any other condition that in the Investigator's opinion suggests an elevated&#xD;
             risk of arterial or venous thromboembolic disease.&#xD;
&#xD;
         14. Has uncontrolled thyroid disorder.&#xD;
&#xD;
         15. Has diagnosis of hereditary angioedema.&#xD;
&#xD;
         16. Has hyperlipidemia on screening.&#xD;
&#xD;
         17. Has uncontrolled diabetes mellitus.&#xD;
&#xD;
         18. Subjects with abnormal significant liver function tests.&#xD;
&#xD;
         19. Has a significantly abnormal cervical cancer screening test at screening visit.&#xD;
&#xD;
         20. Subjects with chlamydial or gonorrheal infection.&#xD;
&#xD;
         21. Has unexplained vaginal bleeding.&#xD;
&#xD;
         22. History of known or suspected hepatitis B or C infection or high risk for sexually&#xD;
             transmitted disease (STD).&#xD;
&#xD;
         23. Known human immunodeficiency virus (HIV) infection or positive test at screening.&#xD;
&#xD;
         24. Current known active infection of coronavirus disease 2019 (COVID-19) or increased&#xD;
             risk of COVID-19 related morbidity. Subjects who have had previous COVID-19 infections&#xD;
             but have recovered by the time of enrollment visit may be enrolled if there are no&#xD;
             current COVID-19 symptoms; Subjects who had previously received COVID-19 vaccine may&#xD;
             be enrolled irrespective of the timing of vaccination.&#xD;
&#xD;
         25. History of suicidal ideation or attempt, or history of severe depression requiring&#xD;
             hospitalization within the past year.&#xD;
&#xD;
         26. Presence of any other concomitant disease or laboratory result that may worsen under&#xD;
             hormonal treatment based on Investigator's discretion.&#xD;
&#xD;
         27. Positive urine drug screen.&#xD;
&#xD;
         28. Recent history (within prior 12 months) of drug or alcohol abuse or at Investigator&#xD;
             discretion, history greater than 12 months prior and at risk for noncompliance.&#xD;
&#xD;
         29. Participation in an investigational study within 30 days prior to enrollment or&#xD;
             intention to participate within next 13 months.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Prasanna C Ganapathi</last_name>
    <phone>+91 80 6672 8952</phone>
    <email>PrasannaC.Ganapathi@viatris.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mylan Investigator Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33409</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mylan Investigator Site</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 20, 2021</study_first_submitted>
  <study_first_submitted_qc>November 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 1, 2021</study_first_posted>
  <last_update_submitted>November 18, 2021</last_update_submitted>
  <last_update_submitted_qc>November 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Birth Control</keyword>
  <keyword>Pregnancy Prevention</keyword>
  <keyword>Contraceptive</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Contraceptive Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

